Introduction: Ambulatory blood pressure monitoring (ABPM) is a sensitive method used to determine whether small changes in blood pressure (BP) and heart rate (HR) are induced by new drugs. This randomized, double-blind, placebo-controlled ABPM trial was used to characterize the BP and HR profile of the novel β3-adrenergic receptor agonist vibegron in patients with OAB.

Separate post hoc analyses of the PROSPER (n=905) and ARCHES (n=1047) studies investigated post-treatment prostate-specific antigen (PSA) decline and baseline PSA, respectively, in patients treated with enzalutamide and androgen deprivation therapy (ADT), for potential prognostic value and implications for patient care.

Introduction:Achieving and maintaining effective testosterone(T) suppression with androgen deprivation therapies(ADTs) is fundamental for advanced prostate cancer(PCa) treatment. However, T levels may exceed castrate level(50/20ng/dL) between injections, especially with delayed subsequent doses1. PCa patients are particularly vulnerable during a pandemic and are likely to receive injections late and/or miss scheduled injections due to reluctance to visit clinics/hospitals. During a pandemic, physician/hospital visits should be minimized. 6-month formulations generally only require two visits a year, and therefore, only two opportunities for “late” injections if dosing schedule adherence is not maintained. Nurses play a critical role in ensuring timely dosing to prevent potential T breakthroughs, performing regular tests to monitor effectiveness, and educating patients on therapy options. We present an analysis of PCa patients treated with 2 most common ADTs.

Urinary retention or incomplete bladder emptying leads to negative health outcomes, reduced quality of life and increases in healthcare resource utilization. Intermittent self-catheterization (ISC) reduces user time exposure to the catheter and may be associated with fewer urinary symptoms, fewer UTIs, improved Quality of life, reduced resource utilization, and increased overall satisfaction. Patient-reported outcomes on long term data about the daily experiences and habits of intermittent catheter use is lacking.

Objective: The aim of this study in patients with overactive bladder (OAB) was to investigate the impact of a nurse navigator (defined as a healthcare professional focused on patient-centered care) on advancing patients to third line therapy with onabotulinumtoxinA (onabotA) and subsequent treatment utilization.

Introduction: Reductions in bothersome symptoms of overactive bladder (OAB) are reported to demonstrate improvement in clinical trials, often without interpreting meaningfulness to patients. In the 12-week phase 3 EMPOWUR trial, vibegron significantly reduced micturitions, urgency episodes, and urge urinary incontinence (UUI) episodes (in patients with OAB wet) vs placebo (P

Introduction: Overactive bladder (OAB) is characterized by urgency and frequency with (OAB-wet) or without (OAB-dry) urge urinary incontinence (UUI). In the phase 3 EMPOWUR trial, vibegron—a β3-adrenergic agonist approved for the treatment of adult patients with OAB—was associated with significant improvements in daily number of urgency episodes (the need to urinate immediately) and micturitions vs placebo (P